Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.53 |
| ▸ | CTSS | P25774 | 5/20 | 0.53 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19245139 | 1.00 | CTSK (0.53) | CTSKCTSSPPARAPPARGHDAC4 | |
| SCHEMBL18762606 | 0.97 | CTSK (0.56) | CTSKCTSSPPARAPPARGHDAC4 | |
| SCHEMBL31407449 | 0.97 | CTSK (0.56) | CTSKCTSSPPARAPPARGHDAC4 | |
| SCHEMBL3726757 | 0.96 | CTSK (0.58) | CTSKCTSSPPARAPPARGHDAC4 | |
| SCHEMBL31551112 | 0.96 | CTSK (0.58) | CTSKCTSSPPARAPPARGHDAC4 | |
| SCHEMBL3726766 | 0.96 | CTSK (0.58) | CTSKCTSSPPARAPPARGHDAC4 | |
| SCHEMBL25381677 | 0.94 | CTSS (0.56) | CTSKCTSSPPARAPPARGHDAC4 | |
| SCHEMBL19066733 | 0.94 | CTSS (0.56) | CTSKCTSSPPARAPPARGHDAC4 | |
| SCHEMBL25835305 | 0.90 | CTSK (0.45) | CTSKCTSSPPARAPPARGHDAC4 | |
| SCHEMBL18762615 | 0.89 | CTSK (0.54) | CTSKCTSSHDAC4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| EP-4066896-A1 | G9A INHIBITOR | RIKEN (JP) | 2022-10-05 | — | — | EP | disclosed |
| WO-2005113581-A1 | SUBSTITUTED PROLINES AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127046-A1 | G9a INHIBITOR | EZH2, BMI1, DOT1L | CTSK 4641/4885CTSS 4716/4885PPARA 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.